Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA

P Konstantinova1, W de Vries1,2, J Haasnoot1, O ter Brake1, P de Haan2 and B Berkhout1
1Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
2Viruvation BV Wassenaarseweg 72, Leiden, The Netherlands

Inhibition of virus replication by means of RNA interference has been reported for several important human pathogens, including human immunodeficiency virus type 1 (HIV-1). RNA interference against these pathogens has been accomplished by introduction of virus-specific synthetic small interfering RNAs (siRNAs) or DNA constructs encoding short-hairpin RNAs (shRNAs). Their use as therapeutic antiviral against HIV-1 is limited, because of the emergence of viral escape mutants. In order to solve this durability problem, we tested DNA constructs encoding virus-specific long-hairpin RNAs (lhRNAs) for their ability to inhibit HIV-1 production. Expression of lhRNAs in mammalian cells may result in the synthesis of many siRNAs targeting different viral sequences, thus providing more potent inhibition and reducing the chance of viral escape. The lhRNA constructs were compared with in vitro diced double-stranded RNA and a DNA construct encoding an effective nef-specific shRNA for their ability to inhibit HIV-1 production in cells. Our results show that DNA constructs encoding virus-specific lhRNAs are capable of inhibiting HIV-1 production in a sequence-specific manner, without inducing the class I interferon genes.

Gene Therapy (2006) 13, 1403–1413. doi:10.1038/sj.gt.3302786; published online 18 May 2006

Keywords: HIV-1; RNA interference; lhRNA

Introduction

RNA silencing or RNA interference (RNAi) is an evolutionary conserved sequence-specific post-transcriptional gene regulation mechanism that plays an important role in cell differentiation and development.1–3 In addition, RNAi serves as a defence mechanism against invading viruses and transposons.4–6 RNA interference is triggered by double-stranded RNA (dsRNA) molecules, which are processed in the cytoplasm by the dsRNA-specific endonuclease Dicer into 19–24 nucleotides (nt) small interfering RNAs (siRNAs) or micro-RNAs (miRNAs).7 These si/miRNAs are incorporated into the multiprotein RNA-induced silencing complex (RISC) that guides the recognition and ultimately the cleavage or translational repression of complementary single-stranded RNA, such as messenger RNA or viral genomic RNA.8–10

RNA interference has been employed to inhibit the replication of a wide range of viruses, including the human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV), hepatitis B virus (HBV), dengue virus, poliovirus, influenza virus, herpesvirus and picornaviruses.11 Human immunodeficiency virus type 1 virions contain a single-stranded RNA genome that is a putative RNAi target. After entry into a host cell the genomic RNA is reverse transcribed into dsDNA, which is integrated into the host chromosomal DNA. Newly synthesized unspliced genome-length and spliced subgenomic viral RNAs are possible targets for RNAi in the cytoplasm. It has recently been reported that HIV-1 encodes a suppressor of RNAi, the Tat protein, indicating that HIV-1 replication is controlled by RNAi in human cells.12 Due to its sequence specificity, RNAi is a potentially powerful and selective method for intracellular immunization against HIV-1 infection. RNA interference-mediated suppression of HIV-1 replication has been accomplished by synthetic siRNAs in a transient manner13–16 and by short-hairpin RNA (shRNA)-expression vectors in stably transfected cells.17–19 Despite potent inhibition, the use of siRNA/shRNA as a therapeutic antiviral is limited, because of the rapid emergence of HIV-1 escape mutants.20–22 Minor sequence changes in the target sequence, sometimes even a single point mutation, are sufficient to abrogate the inhibition of virus replication. Strategies to reduce the chance of viral escape include the simultaneous use of multiple siRNAs22,23 or the use of long-hairpin RNA (lhRNA, a single-hairpin molecule) or long dsRNA (two complementary molecules that form a duplex).24 Another possibility is the use of miRNA-based approaches, which do not require perfect sequence complementarity.25,26

Several reports describe efficient RNAi induction by lhRNA and long dsRNA as in vitro generated transcripts that are transfected into cells or as gene constructs that produce the transcripts intracellularly. Transfection of pre-implantation mouse embryo cells, undifferentiated
Gene Therapy

nef potently as shRNAs and long dsRNA can inhibit HIV-1 at least as strongly as
that stably express an shRNA targeted to viral nef sequences (8519–8818). Double-stranded RNA nef2 is a duplex of two separate, complementary molecules that form a duplex were designed to target tat, rev and nef sequences as indicated in Figure 1.

Inhibition of HIV-1 by lhRNA

We tested whether in vitro transcribed and annealed nef2 dsRNA and its in vitro diced product si-nef2, a mixture of nef-specific siRNAs, can inhibit HIV-1. Nef2 dsRNA of 300 bp was diced in vitro to create si-nef2 RNAs of approximately 21 bp (Figure 2a). We cotransfected 500 ng of the HIV-1 molecular clone pLAI with and without 10 ng inhibitory RNA in human embryonic kidney (HEK) 293T cells. DNA of pRL expressing Renilla luciferase was included in the transfection mixtures to monitor cell viability and possible non-specific effects, for example, due to IFN induction by dsRNA. Virus production was measured by CA-p24 enzyme-linked immunosorbent assay (ELISA) in the culture supernatant 3 days after transfection. The amount of virus production without an inhibitory RNA, generally in the 50–250 ng/ml CA-p24 range, was set at 100%. nef2 dsRNA induced a significant decrease in CA-p24 production, but even more pronounced level of inhibition was obtained with diced si-nef2 (Figure 2b). This can be explained by the fact that si-nef2 bypasses the intracellular dicing step, which may be a limiting factor in the RNAi pathway.

One of the hallmarks of the RNAi is its sequence specificity. Therefore, we tested if nef2 dsRNA and its in vitro diced product si-nef2 would inhibit pGL3-Nef reporter, in which 250 nt from the nef2 target sequence was placed downstream of the luciferase reporter gene.21 Nef2 dsRNA induced a decrease in luciferase expression, but an even more pronounced level of inhibition was

Results

RNA interference targets in the human immunodeficiency virus type 1 genome

It has previously been demonstrated that HIV-1 replication can be inhibited by siRNAs and shRNAs directed against viral targets.11,14,15,16,18,19,44 Most of the active siRNAs against HIV-1 are targeted to the early regulatory tat, rev and nef genes.19,20,45,46 Interference with an early stage of the HIV-1 replication cycle may be beneficial. For this reason, the DNA constructs encoding lhRNAs (a single-hairpin molecule) and long dsRNAs (two complementary molecules that form a duplex) were designed to target tat, rev and nef sequences as indicated in Figure 1.
was measured. 72 h cells were lysed and firefly and renilla luciferase expression control. Transfections were performed as described above. After experiments. (c) Cotransfection of human embryonic kidney (HEK) 293T cells with 10 ng of the indicated RNA, 500 ng pLAI and 2.5 ng pRL as an internal control. Transfections were performed with Lipofectamine 2000 and 1.5 × 10⁶ cells. Virus production was measured in the culture supernatant 2 days after transfection. CA-p24 values are given as percentage of the pLAI production without inhibitory RNA. Standard error bars represent the means of four independent experiments. (c) Cotransfection of HEK 293T cells with 10 ng of the indicated dsRNA, 100 ng pGL3-Nef and 2.5 ng pRL as an internal control. Transfections were performed as described above. After 72 h cells were lysed and firefly and renilla luciferase expression was measured.

obtained with diced si-nef2 (Figure 2c). The pRL expression was not influenced (results not shown). In fact, in vitro diced si-nef2 is a much more effective inhibitor than the in vitro synthesized short-hairpin inhibitor sh-nef RNA, which was included as a positive control. We next tested the inhibitory potential of nef2 dsRNA in the 1–1000 ng range. At amounts above 10 ng, non-specific decrease of Renilla reniformis luciferase (RL) expression was observed, which is most likely due to IFN induction (results not shown, see also Figure 8). The high level of inhibition obtained with low amounts of dsRNA convinced us to design and test a series of DNA expression plasmids encoding long HIV-1-specific dsRNAs.

**Low-level inhibition of human immunodeficiency virus type 1 by long-hairpin RNA expression plasmids**

To make lhRNA constructs, we cloned the HIV-1 tat, rev and nef gene sequences as inverted repeats under the transcriptional control of the constitutive EF1α promoter (Figure 3). These vectors should produce lhRNA, a long-hairpin structure consisting of an approximately 300 bp stem and a 46 nt loop. During transcription of the inverted sequences, an RNA molecule is made, which folds back on itself to form a hairpin structure with a stem of approximately 300 bp. In silico RNA analysis with the Mfold program[2] confirms the folding of these extended hairpins (data not shown). We tested inhibition of HIV-1 in several mammalian cell lines (C33A, HEK 293T and Vero). Cotransfection of pLAI with the pEF1α-tat, pEF1α-rev or pEF1α-nef1 vectors resulted in marginal inhibition of HIV-1 production in C33A and HEK 293T cells, and only the pEF1α-tat vector was inhibitory in Vero cells (Figure 4a).

We also designed a control pEF1α-green fluorescent protein (GFP) plasmid that expresses a similar extended lhRNA against GFP mRNA. No inhibition of virus production was observed with the control pEF1α-GFP vector, thus providing additional evidence for the specificity of lhRNA-mediated inhibition of HIV-1 production. We previously demonstrated potent inhibition of HIV-1 replication in T cells that stably express an shRNA targeted to viral nef gene sequences.[7] Therefore, if lhRNA inhibits HIV-1 potently, it should be at least as active as the sh-nef control. Unlike the results with in vitro synthesized nef2 dsRNA, either diced or not, all lhRNA constructs (tat, rev and nef1) were much less potent inhibitors than the control sh-nef construct, which produces the short hairpin from a polymerase III promoter. Because pEF1α-tat and pEF1α-nef1 were slightly more effective than pEF1α-rev in C33A and 293T cells, we focused on these lhRNAs in the subsequent experiments.

**Inducible long-hairpin RNA expression**

In order to avoid innate viral responses or possible other side effects and to obtain controllable expression of lhRNA, we placed the expression of the lhRNAs tat and nef under control of inducible promoters: (i) the doxycycline (dox) inducible Tet system[30] and (ii) the Tat-inducible long-terminal repeat (LTR) promoter/enhancer of HIV-1[49] (Figure 3). The latter system seems ideally suited to restrict lhRNA expression to cells that are infected by HIV-1, thus providing a unique safety feature. Furthermore, we replaced the 46 bp spacer between the repeats by the 1000 bp EF-1α intron, since it has been shown that this improves the inhibitory potential of lhRNA-encoding DNA constructs.[30]

The Tet-On system is based on the specific, high-affinity binding of the rtTA trans-activator to the tet operator (tetO) in the presence of dox, triggering transcription of downstream genes. This system has recently been used to express synthetic miRNA precursors in mouse or human genomes, following trans-
Inhibition of HIV-1 by lhRNA

P Konstantinova et al

Inhibition of HIV-1 by lhRNA

Gene Therapy

Figure 3 Expression vectors for long-hairpin RNA (lhRNA), double-stranded RNA (dsRNA) and short-hairpin RNA (shRNA). Long-hairpin RNAs were created by cloning the 300-nucleotide (nt) inverted repeats from tat, rev and nef (see Figure 1) downstream of the EF1α, 7tetO or long-terminal repeat (LTR) promoters. The 1 kb EF1α intron is positioned downstream of the EF1α promoter. A schematic representation of the final hairpin structures is shown on the right. In pEF1α constructs, the two complementary RNA strands are separated by a 46 nt loop. In the p7tetO and pLTR constructs, the complementary sequences are separated by a 1 kb spacer that contains splice donor and acceptor sites. Vector pLTR-nef1 is a derivative of pLTR-nef1 in which the human immunodeficiency virus type 1 (HIV-1) leader sequence (Ψ, 76–630, marked as a gray box) was inserted. The predicted transcript will have the Ψ domain upstream of the RNA hairpin. All transcripts contain a polyadenylation signal (pA) downstream of the hairpin sequences. Vector pT7-nef2 has 300 basepairs (bp) long double-stranded nef sequences flanked by T7 promoters (T7) and terminators (φ) at both 5’ and 3’ ends. Two separate complementary RNA chains, potentially capable of forming dsRNA, are transcribed from the convergent promoters by T7 RNA polymerase (encoded by expression plasmid pT7-pol). Vectors p7sh-nef and pH1sh-nef express sh-nef from the T7 and H1 promoters, respectively.

Production with retroviral or lentiviral vectors.53 Vector pLAI was cotransfected with p7 tetO-tat or p7 tetO-nef1 (Figure 3). We also included pCMV-rtTA and the control plRl, and dox was added 4 h later. p7 tetO-tat or p7 tetO-nef1 conferred no or very poor inhibition of HIV-1 as compared to the sh-nef control (Figure 4b). The potency of the lhRNAs was not increased by varying the ratio of lhRNA-expression vector to pCMV-rtTA or the dox concentration. Moreover, a non-specific decrease of RL expression was observed at higher pCMV-rtTA concentrations, which is probably due to promoter squelching (results not shown).

In order to restrict lhRNA expression to cells that are infected with HIV-1, the inverted tat and nef repeats were cloned downstream of the Tat-inducible LTR promoter/enhancer of HIV-1, resulting in plasmids pLTR-tat and pLTR-nef1 (Figure 3). A Tat-inducible Pol I promoter expressing anti-HIV shRNA has been described for inhibition of HIV-1 gene expression in mammalian cells.52 In this setting, lhRNA or shRNA expression is activated in trans by the Tat protein encoded by HIV-1. To avoid self-targeting, we deleted a large part of the U3 region (up to position −179) in the LTR promoter of both LTR expression plasmids that overlaps with the nef coding domain (323 nt). Human embryonic kidney 293T cells were cotransfected with pLAI and pLTR-tat or pLTR-nef1. Both expression plasmids inhibit virus production by approximately 60% (Figure 5a).

Directing long-hairpin RNA along viral pathways

The poor inhibitory potency of the different lhRNA constructs could be due to expression problems, but the lhRNA may also encounter difficulties in entering or proceeding along the RNAi pathway. In order to increase the efficacy of the lhRNA molecules, we cloned the HIV-1 leader sequence (Ψ) between the LTR and nef1 in pLTRΨ-nef1 (Figure 3). Control plasmid pLTRasΨ-nef1 was made with the Ψ element inserted in antisense orientation. Previously, we reported that sequences from the 5' untranslated leader of the HIV-1 genome, such as the RNA dimerization signal, can be used to inhibit HIV expression in trans.53 We presumed that Ψ should bring the antiviral RNA along viral pathways, conferring a stronger inhibitory effect. Indeed, in HEK 293T cells transfected with pLAI and pLTRΨ-nef1, HIV-1 production was almost completely inhibited (Figure 5a). The level of inhibition conferred by pLTRΨ-nef1 is comparable to that of the positive control sh-nef. Inhibition is specific and not due to a more general cell toxicity problem because no significant decrease in RL expression was observed (results not shown). Control plasmid pLTRasΨ-nef1 was much less effective in inhibiting HIV-1 production, with a potency comparable to that of the original pLTR-nef1 construct. Plasmid pLTRΨ, in which the nef1 sequence has been deleted, failed to inhibit HIV-1 production (Figure 5b). This result indicates that the presence of the Ψ element enhances nef1-mediated inhibition of HIV-1, but the presence of the nef1 sequence is essential for the potent effect of pLTRΨ-nef1.

Transcript Ψ-nef1 expression from the LTR promoter is induced by pLAI-encoded Tat protein. Because pLAI gene expression is strongly inhibited by pLTRΨ-nef1, a negative feedback loop may have been established, which leads to an underestimation of the inhibitory potential of pLTRΨ-nef1. We therefore added a Tat-expression plasmid (pcDNA3-Tat) in trans to secure pLTRΨ-nef1 expression. Human embryonic kidney 293T cells were transfected with 100 ng pLAI and 10–100 ng pLTRΨ-nef1 with or without pcDNA3-Tat. As shown in Figure 5c, pronounced HIV-1 inhibition was obtained with as little as 10 ng pLTRΨ-nef1. The presence of
additional Tat did not significantly improve the inhibition conferred by pLTR\textsuperscript{C-nef1}, indicating that the background LTR promoter activity produces sufficient amounts of the inhibitory transcript.

We next wanted to test if the potent pLTR\textsuperscript{C-nef1} construct was able to inhibit HIV-1 variants that escaped from the sh-nef inhibitor. We described previously a series of viral escape variants with mutations or deletions in the targeted nef sequence.\textsuperscript{19} We selected mutant R1 with a 106 nt deletion that includes the complete sh-nef target sequence and mutant R3\textsuperscript{0} with two point mutations in the nef sequence.

**Figure 4** Marginal inhibition of human immunodeficiency virus (HIV-1) production by pEF1α- and p7tetO-driven long-hairpin RNA (lhRNA) constructs. (a) Cells (C33A, human embryonic kidney (HEK) 239T and Vero) were lipofectamine-transfected with 500 ng pLAI, 500 ng inhibitory construct, 3 ng pCMV-rtTA and 2.5 ng pRL. Vector pEF1α-green fluorescent protein (GFP) was used as a control expressing an irrelevant lhRNA against GFP. Vectors pH1sh-nef and the empty vector were used as negative and positive controls, respectively. Virus production was determined as described in the legend to Figure 2. Standard error bars represent the means of three independent experiments. The sh-nef control construct was not tested in C33A cells. (b) HEK 239T cells were cotransfected with 100 ng of pLAI and 100 ng pLTR-tat, pLTR-nef1, pLTR\textsuperscript{C-nef1} or pH1sh-nef. On the y-axis, the CA-p24 values (ng/ml) are presented. (c) Effect of the trans-activator protein Tat on the inhibitory effect of pLTR\textsuperscript{C-nef1}. pLAI (100 ng) was cotransfected with 0–10–30–100 ng pLTR\textsuperscript{C-nef1} with or without 20 ng pcDNA3-Tat. Virus production was determined as described in the legend to Figure 2. Standard error bars represent the means of four independent experiments.

**Figure 5** Antiviral long-hairpin RNA (lhRNA) production from the human immunodeficiency virus (HIV)-inducible long-terminal repeat (LTR) promoter. (a) Inhibition of HIV-1 production by lhRNA expressed from the Tat-inducible HIV-1 LTR. Human embryonic kidney (HEK) 239T cells were cotransfected with 100 ng of pLAI and 100 ng of pLTR-tat, pLTR-nef1, pLTR\textsuperscript{Ψ-nef1} or pH1sh-\textsuperscript{Ψ-nef1}. Equal amounts of a pH1sh-nef expression vector and the empty vector were added as positive and negative controls, respectively. (b) Sequence-specific inhibition of HIV-1 production by pLTR\textsuperscript{Ψ-nef1}. HEK 239T cells were cotransfected with 100 ng of pLAI and 10 ng of pLTR\textsuperscript{Ψ}, pLTR\textsuperscript{Ψ-nef1} or pH1sh-nef. On the y-axis, the CA-p24 values (ng/ml) are presented. (c) Effect of the trans-activator protein Tat on the inhibitory effect of pLTR\textsuperscript{Ψ-nef1}. pLAI (100 ng) was cotransfected with 0–10–30–100 ng of pLTR\textsuperscript{Ψ-nef1} with or without 20 ng of pcDNA3-Tat. Virus production was determined as described in the legend to Figure 2. Standard error bars represent the means of five independent experiments.
Inhibition of human immunodeficiency virus type 1 by cytoplasmically expressed ds-nef2

RNA interference is mainly a cytoplasmic process, and putative pathways in nuclear export of lhRNAs may thus hamper their inhibitory activity. In order to test whether there is a difference between the RNAi-inducing capacity of dsRNAs produced in the nucleus or cytoplasm of cells, we expressed dsRNA targeted to nef in mammalian cells. 32,34,35,37 Interestingly, full-length dsRNA is not potent in the absence of T7-polymerase. This can explain the slight inhibition of gene expression obtained with pT7-nef2 in the absence of T7-pol inducer. A high amount of T7-polymerase accumulating in the cytoplasm of cells may induce the innate antiviral IFN response. To measure the RNA expression levels of selected lhRNA-expression constructs, we performed a reverse transcriptase-polymerase chain reaction (RT-PCR) assay with nef-specific primers. All constructs expressed nef RNA (Figure 7). Notably, pT7-nef2 produced low amounts of RNA even in the absence of the T7-pol inducer. No nef-specific fragment was detected in mock-transfected cells or in cells transfected with poly(I:C).

Endogenously expressed long-hairpin RNA and long double-stranded RNA do not induce the interferon response

It has been reported that introduction of dsRNAs longer than 30 bp in mammalian cells induces the innate antiviral IFN response. We determined IFN-β induction by RT-PCR in HEK 293T cells upon transfection with in vitro made nef2 dsRNA and DNA constructs encoding pEF1-nef1, pLTR-nef1, pLTR-nef1, pT7-nef2 or pH1sh-nef. Transfection of 1 μg poly(I:C) in HEK 293T cells upon transfection with poly(I:C), a known inducer of IFN and other cytokines, was used as a positive control. The lhRNA- and sh-nef-expression plasmids did not induce detectable levels of IFN-β mRNA (Figure 8). Both nef2 dsRNA and poly(I:C) controls induced high amounts of the IFN-β mRNA.

Discussion

The use of synthetic siRNAs or shRNA-expression plasmids as inducers of RNAi-based therapy against HIV-1 faces the major obstacle of the emergence of virus escape variants. Similar to the combined use of antivirals in highly active antiretroviral therapy (HAART), one could design an RNAi therapy with extended lhRNA/ dsRNA. Endogenous expression of two long complementary RNAs, with the potential to form an extended dsRNA duplex, leads to specific suppression of gene expression in mammalian cells.22,34,35,37 Interestingly, full-length dsRNAs could not be detected, suggesting that
processing by Dicer precludes their accumulation in the cytoplasm. Long dsRNAs are indeed processed in vitro by the RNAi machinery into multiple active siRNAs.55,56 Several lines of evidence show that lhRNAs induce gene silencing by the RNAi mechanism. Inhibition of Dicer abrogated the gene silencing induced by lhRNA against GFP, indicating that silencing was mediated by RNAi.32 These results suggest that long dsRNA is well tolerated in mammalian cells, most likely because it is processed rapidly by the RNAi machinery. It is also relevant to mention that mammalian cells may naturally produce dsRNA derived from repetitive and transposable elements.57,58 A recently performed bioinformatics study revealed the presence of at least 4520 full-length transcripts, which form sense–antisense gene pairs in the human genome.59

We designed a set of anti-HIV-1 lhRNA/dsRNA-expression constructs and compared their ability to inhibit virus production with a very potent shRNA-based inhibitor that we described previously.19 Ideally, a single lhRNA should provide more potent inhibition of HIV than an shRNA. An additional advantage of lhRNA is that it does not require predetermination of optimal shRNAs and HIV-1 target sequences because multiple effective siRNAs will be produced. A potential disadvantage of the use of lhRNA as therapeutic is that the multiple siRNAs are more likely to cause off-target effects.

Figure 6 Inhibition of human immunodeficiency virus type 1 (HIV-1) by cytoplasmically expressed long double-stranded RNA (dsRNA). (a) pT7-luc (100 ng) construct was cotransfected in human embryonic kidney (HEK) 293T cells with or without 30 ng pT7-pol. At 2 days after transfection, cells were lysed and the expression of firefly luciferase was measured. (b) pT7-nef2 (100 ng) and pT7sh-nef vectors were linearized 3′ of the T7 termination signal with XbaI and BsmBI, respectively, and cotransfected with 100 ng pLAI, 30 ng pT7-pol and 2.5 ng pRL in HEK 293T cells. Two separate complementary RNA chains, potentially forming dsRNA, are transcribed in the cell from convergent T7 promoters. Equal amounts of a pH1sh-nef expression vector and the empty vector were added as positive and negative controls, respectively. Cotransfections were also performed without pT7-pol to check for non-specific effects of the T7 plasmids. Virus production was determined as described in the legend to Figure 2. Standard error bars represent the means of four independent experiments. Cells were lysed 2 days after transfection to measure Renilla luciferase. (c) Sequence-specific inhibition of the pGL3-Nef reporter, containing the 250-nucleotide (nt) nef2 target sequence downstream of the luciferase coding domain, by pT7-nef2. HEK 297T cells were cotransfected with 100 ng of pGL3-Nef, 100 ng pT7-nef2, 30 ng pT7-pol and 2.5 ng pRL, pH1sh-nef (10 ng) expression vector and the empty vector were added as positive and negative controls, respectively. (d) Titration of T7 polymerase. pLAI (100 ng) was cotransfected with increasing amounts (0–3–10–30–100 ng) of pT7-pol and 100 ng pT7-nef2 or pT7sh-nef.
Long-hairpin RNAs expressed from constitutive (EF1a) and inducible (7tetO, HIV-1 LTR) promoters inhibited HIV-1 production marginally, but we demonstrated potent and specific HIV-1 silencing with modified DNA constructs. The most active constructs either link the lhRNA to viral RNA sequences (Ψ) or express the long dsRNA directly in the cytoplasm, suggesting that translocation of dsRNA from the nucleus to the cytoplasm is a crucial step for these molecules to enter the cytoplasmic RNAi pathway. It is widely accepted that RNAi is a cytoplasmic process, as most protein components of the RNAi pathway, including Argonaute 2, are found in the cytoplasm. As most reports on IFN induction by long dsRNA in inducing the IFN response. Human embryonic kidney (HEK) 293T cells (1.5 × 10⁶) were transfected with pLAI and the indicated lhRNA/double-stranded RNA (dsRNA)-expression constructs using Lipofectamine 2000. Construct pT7-nef2 was cotransfected with pT7-pol. Renilla luciferase (pRL) was used as an internal control. The pUC19 plasmid was used as a negative control. In vivo transcribed ds-nef2 RNA and poly (I:C) act as positive controls for IFN-β induction. Two separate transfections were performed, which were processed for either IFN-β mRNA expression or renilla measurement. No significant differences in Renilla expression were measured, except for the toxic treatment with ds-nef2 RNA and poly(I:C) results not shown. In addition, we measured CA-p24 in the supernatant, which showed the inhibition characteristics described earlier. Total RNA was isolated from the cells 24 h after transfection. The IFN-β expression level was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). β-Actin mRNA expression was analyzed as an internal control. PUC19 RT- and poly (I:C) RT- are control reactions without RT step.

We showed that endogenously expressed lhRNA and dsRNA do not activate the innate antiviral response. A similar result has recently been described in literature. Exposure of cells to a 50 bp in vitro synthesized dsRNA induces the production of class I IFNs, but not when such molecules are expressed in the cell from a DNA construct with the U6 promoter. Modification of lhRNAs expressed from a Pol III promoter by inclusion of multiple G:U wobbles induced RNAi without any non-specific effects. In fact, most reports on IFN induction by long dsRNAs in mammalian cells are based on transfection of cells with in vitro synthesized dsRNAs. Apparently, endogenously produced dsRNA is less active than exogenous dsRNA in inducing the IFN response. This finding may have a major impact on the further development of RNAi-based antiviral strategies.

RNA interference-based gene therapy against HIV-1 seems to be a viable option, either as mono-therapy or combined with traditional drug therapy. The outgrowth of RNAi-resistant virus mutants presents a major obstacle for all sequence-specific inhibitory strategies. The simultaneous targeting of multiple conserved targets by lhRNA may confer increased robustness to future RNAi therapies. We will focus on optimization of the DNA constructs encoding HIV-1-specific lhRNAs, for example, the type of promoter used and the structure of the lhRNA. We will also test stable expression of these constructs in HIV-susceptible cells. These cell lines will be extensively tested for the emergence of RNAi-resistant virus variants.
Materials and methods

DNA constructs and RNA transcripts

The full-length HIV-1 molecular clone pLAI was used to produce wild-type virus and to study inhibition by lhRNAs directed against the tat, rev or nef sequences. A detailed description of the construction of all lhRNA-expression constructs is available as Supplementary information. Plasmid pcDNA3-T7pol, expressing bacteriophage T7 polymerase (pT7-pol, a kind gift of Dr Jean-Marc Jacque, University of Massachusetts Medical School, Worcester, MA, USA), pGL3-Nef and pH1sh-nef have been described previously.14,19

The Mfold program (http://www.bioinfo.rpi.edu/applications/mfold) was used to check the correct folding of extended hairpins.

In vitro transcription and dicing of ds-nef2 RNA

The ds-nef2 RNA was in vitro transcribed with the Megashortscript T7 transcription kit (Ambion, Austin, TX, USA) from the nef2 pCR template that contains convergent T7 promoters and terminators. The sh-nef RNAi inducer was transcribed in vitro from the BamHI-linearized pT7sh-nef vector. ds-nef2 RNA (1 μg) was diced in vitro at 37°C for 18–20 h using recombinant Dicer enzyme (Stratagene, Cedar Creek, TX, USA). The full-length ds-nef2 RNA, the cleaved si-nef2 (a mix of siRNAs derived from ds-nef2) and sh-nef were purified through MicroSpin G-25 column (Amersham Biosciences, Piscataway, NJ, USA). To remove undigested dsRNA from the dicing reaction, the si-nef2 was purified further on a Microcon YM-100 column (Millipore, Billerica, MA, USA). si-nef2 RNA was analyzed on 2% MetaPhor (BMA, Sanver Tech, The Netherlands) alongside a 20 bp DNA marker (Gensura, San Diego, CA, USA).

Cell culture and transfections

Human embryonic kidney 293T, C3A cervix carcinoma and African green monkey kidney Vero cells were grown as a monolayer in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FCS) (Hybond, Escondido, CA, USA), essential minimum medium with non-essential amino acids, penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C and 5% CO₂. At 1 day before transfection, cells were trypsinized, resuspended in DMEM and seeded in 24-well plates at a density of 1.5 × 10⁵ cells per well. Cells were cotransfected with 100–500 ng pLAI and 1–1000 ng in vitro transcribed ds-nef2 RNA and in vitro diced si-nef2 or 10–500 ng lhRNA (tat, rev, nef1) expression constructs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Virus production was determined by measuring the CA-p24 levels in the culture supernatant by ELISA (Abbott, Abbott Park, IL, USA) as described previously.71 For firefly luciferase measurements, cells were cotransfected with 100 ng pGL3-Nef and 10 ng in vitro transcribed ds-nef2 RNA and in vitro diced si-nef2 or 100 ng p17-nef and 100 ng p17-pol. In all experiments, vector pRL (2.5 ng) (Promega, Madison, WI, USA), expressing RL under the control of the CMV promoter, was added to the transfection mix as a control for variation in transfection efficiency and cell viability. Equal amounts of the pH1sh-nef expression vector or the empty vector were added as positive and negative controls, respectively. Vectors p17-luc and p17-pol were cotransfected in equimolar amounts (100 ng) and FL reporter expression was measured. Briefly, cells were lysed 48–72 h after transfection in 150 μl 1× passive lysis buffer (Promega) by shaking for 30 min at room temperature. The cell lysate was centrifuged for 5 min at 4000 r.p.m. and firefly and renilla luciferase expression was measured in 10 μl supernatant with the dual-luciferase reporter assay system or Renilla luciferase assay system (Promega).

Interferon assay

Induction of the IFN system was measured by a sensitive RT-PCR on the IFN-β mRNA.71 RNA was isolated from HEK 293T cells with the mirVana miRNA isolation kit (Ambion) 24 h after transfection with the long dsRNA constructs. First-strand cDNA was reverse transcribed from approximately 1 μg RNA with random hexamer primers (Invitrogen) using the MMLV-RT enzyme (Invitrogen) according to the manufacturer’s instructions. Approximately 200 ng cDNA was PCR amplified with primers IFN-βF and IFN-βR using standard conditions. Amplification of the β-actin gene was used as an internal control. Transfection of 1 μg poly(I:C) (Amersham Pharmacia Biotech, Piscataway, NJ, USA), a synthetic inosine/cytosine polymer that mimics viral dsRNA, was used as a positive control for IFN-β induction.

RNA of transfected cells was subjected to PCR with nef-specific primers Nef-B/X and AntiU3-att, yielding a 110 bp fragment (Supplementary Table 1).

Acknowledgements

RNAi research in the Berkhourt lab is sponsored by NWO-CW (TOP grant) and Senter-NOVEM (TS grant with Viruvation). We thank Stephan Heynen for performing CA-p24 ELISA; Dr P Midoux (Centre de Biophysique Moleculaire, Orleans, France) for providing us with the pT7-luc plasmid; Dr Jean-Marc Jacque (University of Massachusetts Medical School, USA) for providing the pcDNA3-T7pol expressing vector and Dr E de Jong (University of Amsterdam, The Netherlands) for the kind gift of IFN-β primers.

References

1 Cullen BR. Induction of stable RNA interference in mammalian cells. *Gene Therapy* 2006; 13: 503–508.
2 Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. *Science* 2005; 309: 1519–1524.
3 Filipowicz W. RNA silencing: the nuts and bolts of the RISC machine. *Nucleic Acids Res* 2002; 30: 544–550.
4 Meister G, Landthaler M, Dorsett Y, Tuscher T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. *RNA* 2004; 10: 544–550.
5 Soifer HS, Zaragoza A, Peyvan M, Behlke MA, Rossi JJ. A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. *Nucleic Acids Res* 2005; 33: 846–856.
6 Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in *C. elegans*. *Genes Dev* 2001; 15: 2654–2659.
8 Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–811.

9 Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 293–296.

10 Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001; 107: 309–321.

11 Haasnoot PCJ, Cupac D, Berkhour B. Inhibition of virus replication by RNA interference. J Biomed Sci 2003; 10: 607–616.

12 Bennasser Y, Le SY, Benkirane M, Jeang KT. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 2005; 22: 607–619.

13 Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 2002; 169: 5196–5201.

14 Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435–438.

15 Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8: 681–686.

16 Park WS, Miyano-Kurosaki N, Hayafune M, Nakajima E, Matsuzaki T, Shimada F et al. Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Res 2002; 30: 4830–4835.

17 Anderson J, Banerjea A, Akkina R. Bipartite short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004; 32: 1154–1158.

18 Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004; 32: 1154–1158.

19 Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madireddo M, Bernards R et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601–2609.

20 Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003; 77: 11531–11535.

21 Westerhout EM, Ooms M, Vink M, Das AT, Berkhour B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 2005; 33: 796–804.

22 Berkhour B. RNA interference as an antiviral approach: targeting HIV-1. Curr Opin Mol Ther 2004; 6: 141–145.

23 Brake O, Berkhour B. A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing 2005; 1: 56–65.

24 Yamamoto T, Omoto S, Mizuguchi M, Mizukami H, Okuyama M, Bernards R et al. Double-stranded nel RNA interferes with human immunodeficiency virus type 1 replication. Microbiol Immunol 2002; 46: 819–817.

25 Yeung ML, Bennasser Y, Myers TG, Jiang G, Benkirane M, Jeang KT. Changes in microRNA expression profiles in HIV-1-transfected human cells. Retrovirology 2005; 2: 81.

26 Hariharan M, Scaria V, Pillai B, Brahmacari SK. Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun 2005; 337: 1214–1218.

27 Wianany F, Zernicka-Goetz M. Specific interference with gene function by double-stranded RNA in early mouse development. Nat Cell Biol 2000; 2: 70–75.

28 Billy E, Brondani V, Zhang H, Muller U, Filipowicz W. Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci USA 2001; 98: 14428–14433.

29 Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98: 9742–9747.

30 McMillan NA, Chun RF, Siderovski DP, Galabru J, Toome WN, Samuel CE et al. HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR. Virol 1995; 213: 413–424.

31 Cai R, Carpick B, Chun RF, Jeang KT, Williams BR. HIV-1 Tat inhibits PKR activity by both RNA-dependent and RNA-independent mechanisms. Arch Biochem Biophys 2000; 373: 361–367.

32 Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 1443–1448.

33 Matsumoto S, Miyagishi M, Akashi H, Nagai R, Taira K. Analysis of double-stranded RNA-induced apoptosis pathways using interferon-response noninducible small interfering RNA expression vector library. J Biol Chem 2005; 280: 25687–25696.

34 Ui-Tei K, Zenno S, Miyata Y, Saigo K. Sensitive assay of RNA interference in Drosophila and Chinese hamster cultured cells using firefly luciferase gene as target. FEBS Lett 2000; 479: 79–82.

35 Diallo M, Arenz C, Schmitz K, Sandhoff K, Scheppers U. Long endogenous dsRNAs can induce complete gene silencing in mammalian cells and primary cultures. Oligonucleotides 2003; 13: 381–392.

36 Yi CE, Bekker JM, Miller G, Hill KL, Croshie RH. Specific and potent RNA interference in terminally differentiated myotubes. J Biol Chem 2003; 278: 934–939.

37 Tran N, Raponi M, Dawes IW, Arndt GM. Control of specific gene expression in mammalian cells by co-expression of long complementary RNAs. FEBS Lett 2004; 573: 127–134.

38 Shinagawa T, Ishii S. Generation of Ski-knockdown mice by expressing a long double-strand RNA from an RNA polymerase II promoter. Genes Dev 2003; 17: 1340–1345.

39 Dangl JL, Jones JD. Plant pathogens and integrated defence responses to infection. Nature 2001; 411: 826–833.

40 Caplen NJ, Zheng Z, Falgout B, Morgan RA. Inhibition of viral gene expression and replication in mosquito cells by dsRNA-triggered RNA interference. Mol Ther 2002; 6: 243–251.

41 Qi Y, Zhong X, Itaya A, Ding B. Dissecting RNA silencing in protoplasts uncovers novel effects of viral suppressors on the silencing pathway at the cellular level. Nucleic Acids Res 2004; 32: e179.

42 Waterhouse PM, Graham MW, Wang MB. Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA. Proc Natl Acad Sci USA 1998; 95: 13959–13964.

43 Adelman ZN, Sanchez-Vargas I, Travanty EA, Carlson JO, Beaty BJ, Blair CD et al. RNA silencing of dengue virus type 2 replication in transformed C6/36 mosquito cells transcribing an inverted-repeat RNA derived from the virus genome. J Virol 2002; 76: 12925–12933.

44 Martinez MA, Clotet B, Este JA. RNA interference of HIV replication. Trends Immunol 2002; 23: 559–561.

45 Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20: 500–505.

46 Arteaga HJ, Hinkula J, Dijk-Hard I, Dilber MS, Wahren B, Christenson B et al. Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol 2003; 21: 230–231.

47 Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31: 3406–3415.

48 Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547–5551.

49 Berkhour B, Silbermann RH, Jeang KT. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989; 59: 273–282.
50 Smith NA, Singh SP, Wang MB, Stoutjesdijk PA, Green AG, Waterhouse PM. Total silencing by intron-spliced hairpin RNAs. Nature 2000; 407: 319–320.

51 Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 2005; 102: 13212–13217.

52 Unwalla HJ, Li MJ, Kim JD, Li HT, Ehsani A, Alluin J et al. Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol 2004; 22: 1573–1578.

53 Berkhout B, van Wamel JL. Inhibition of human immunodeficiency virus expression by sense transcripts encoding the retroviral leader RNA. Antiviral Res 1995; 26: 101–115.

54 Zeng Y, Cullen BR. RNA interference in human cells is restricted to the cytoplasm. RNA 2002; 8: 855–860.

55 Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25–33.

56 Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363–366.

57 Lehner B, Williams G, Campbell RD, Sanderson CM. Antisense transcripts in the human genome. Trends Genet 2002; 18: 63–65.

58 Wang Q, Carmichael GG. Effects of length and location on the cellular response to double-stranded RNA. Microbiol Mol Biol Rev 2004; 68: 432–452, table.

59 Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M et al. Antisense transcription in the mammalian transcriptome. Science 2005; 309: 1564–1566.

60 Provost P, Dishart D, Doucet J, Frendevoy D, Samuelson B, Radmark O. Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO J 2002; 21: 5864–5874.

61 Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004; 305: 1437–1441.

62 Sontheimer EJ. Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol 2005; 6: 127–138.

63 Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436: 740–744.

64 Haase AD, Jaskiewicz L, Zhang H, Laine S, Sack R, Gatignol A et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep 2005; 6: 961–967.

65 Watanabe T, Sudoh M, Miyagishi M, Akashi H, Arai M, Inoue K et al. Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype. Gene Therapy 2006, (Epub ahead of print).

66 Akashi H, Miyagishi M, Yokota T, Watanabe H, Hino T, Nishina K et al. Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. Mol BioSys 2005; 1: 382–390.

67 Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15: 188–200.

68 Wolokowicz R, Nolan GP. Gene therapy progress and prospects: novel gene therapy approaches for AIDS. Gene Therapy 2005; 12: 467–476.

69 Peden K, Emerman M, Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 1991; 185: 661–672.

70 Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, Berkhout B. Functional differences between the long terminal repeat transcriptional promoters of HIV-1 subtypes A through G. J Virol 2000; 74: 3740–3751.

71 Lebre MC, Antons JC, Kalinski P, Schuitemaker JH, van Capel TM, Kapsenberg ML et al. Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a Type-1 polarized phenotype in dendritic cells: role of keratinocyte-derived tumor necrosis factor alpha, type 1 interferons, and interleukin-18. J Invest Dermatol 2003; 120: 990–997.

Supplementary Information accompanies the paper on Gene Therapy website (http://www.nature.com/gt)